Effect of recombinant plasmid constructs encoding combinations of dog and horse vegf and bmp2 cDNAs on mesenchymal stromal cell differentiation in vitro


Cite item

Full Text

Abstract

Gene therapy is one of the most promising fields in modern regenerative medicine, though today there is no approved veterinary gene therapy drugs on the market. We have created species-specific gene-engineering plasmid constructs based on plasmid DNA encoding genes of dog and horse vascular endothelial growth factor and bone morphogenetic protein 2, which can be potentially used in treatment of domestic animals traumas and locomotor system disorders In vitro studies of these constructs have shown their effect on stimulation of osteogenic, chondrogenic differentiation and angiogenesis in mesenchymal stem cells in vitro

Full Text

Restricted Access

About the authors

M. N Zhuravleva

Kazan (Volga region) Federal University Kazan, Russia

E. Y Zakirova

Kazan (Volga region) Federal University Kazan, Russia

R. F Masgutov

Kazan (Volga region) Federal University Republican Clinical Hospital Kazan, Russia

V. V Valiullin

Kazan State Medical University Kazan, Russia

R. V Deev

Kazan (Volga region) Federal University Human Stem Cells Institute Kazan, Russia Moscow, Russia

A. A Rizvanov

Kazan (Volga region) Federal University Kazan, Russia

References

  1. Stoll S. M., Calos M.P. Extrachromosomal plasmid vectors for gene therapy. Curr. Opin. Mol. Ther. 2002; 4tIV): 299-305.
  2. Bali A., Bali D., Sharma A. An overview of gene therapy in head and neck cancer. Indian J. Hum. Genet. 2013; 19tIII): 282-90.
  3. Ylä-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol. Ther. 2012; 20(X): 1831-2.
  4. Бродский И.Н., Деев Р.В. Место ангиогенной терапии в программе лечения пациентов с критической ишемией нижних конечностей. Трудный пациент 2014; VI: 16-8.
  5. Chirino A.J., Ary M.L., Marshall S.A., Chirino A.J. Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today. 2004; 9(II): 82-90.
  6. Argyle D.J. Gene therapy in veterinary medicine. Vet. Rec. 1999; 144(XIV): 369-76.
  7. Ely E.R., Avella C.S., Price J.S. et al. Descriptive epidemiology of fracture, tendon and suspensory ligament injuries in National Hunt racehorses in training. Equine Vet. J. 2009; 41tIV): 372-8.
  8. Yates J. Injury and disease in the young thoroughbred racehorse: associations with subsequent racing performance. MSctR) thesis, University of Glasgow; 2010, http://theses.gla. ac. uk/2302/1/2010YatesMScR. pdf
  9. Lipps G. Plasmids: current research and future trends. Dorset: Caister Academic Press; 2008.
  10. Stoll S.M., Calos M.P. Extrachromosomal plasmid vectors for gene therapy. Curr. Opin. Mol. Ther. 2002; 4tIV): 299-305.
  11. Швальб П.Г., Гавриленко А.В., Калинин Р.Е. и др. Эффективность и безопасность применения препарата «Неоваскулген» в комплексной терапии пациентов с хронической ишемией нижних конечностей tIIb-III фаза клинических испытаний). Клеточная трансплантология и тканевая инженерия 2011; 4tIII): 76-83.
  12. Mac Gabhann F., Annex B. H., Popel A. S. Gene therapy from the perspective of systems biology. Curr. Opin. Mol. Ther. 2010; 12(V): 570-7.
  13. Byrne A. M., Bouchier-Hayes D. J., Harmey J.H. Angiogenic and cell survival functions of vascular endothelial growth factor [VEGF). J. Cell Mol. Med. 2005; 9(IV): 777-94.
  14. Sykaras N., Opperman L.A. Bone morphogenetic proteins (BMPs): how do they function and what can they offer the clinician? J. Oral Sci. 2003; 45(II): 57-73.
  15. McKay W.F., Peckham S.M., Badura J.M. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). Int. Orthop. 2007; 31(VI): 729-34.
  16. Baltzer A.W., Lattermann C., Whalen J.D. et al. Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther. 2000; 7(IX): 734-9.
  17. Beamer B., Hettrich C., Lane J. Vascular endothelial growth factor: an essential component of angiogenesis and fracture healing. HSS J. 2010; 6(I): 85-94.
  18. Seamon J., Wang X., Cui F. Adenoviral delivery of the VEGF and BMP-6 genes to rat mesenchymal stem cells potentiates osteogenesis. Bone Marrow Research 2013: 737580. doi: 10 1155/2013/737580
  19. Kaipel M., Schützenberger S., Schultz A. et al. BMP-2 but not VEGF or PDGF in fibrin matrix supports bone healing in a delayed-union rat model. Orthop Res. 2012; 30(X): 1563-9.
  20. Kakudo N., Kusumoto K., Wang Y.B. et al. Immunolocalization of vascular endothelial growth factor on intramuscular ectopic osteoinduction by bone morphogenetic protein-2. Life Sci. 2006; 79(IXX): 1847-55.
  21. Bunnell B.A., Flaat M. Adipose-derived stem cells: isolation, expansion and differentiation. Methods 2008; 45(II): 12-5.
  22. Катина М.Н., Гайфуллина Р.Ф., Хаятова З.Г. и др. Выделение, культивирование и дифференцировка мультипотентных мезенхимных стромальных клеток из жировой ткани крыс Rattus norvegicus и хомяков Mesocricetus auratus. КТТИ 2012; 7(III): 82-8.
  23. Ризванов А.А., Журавлева М.Н., Закирова Е.Ю. др. Способ стимуляции репаративного ангио- и остеогенеза в ветеринарии с помощью генетических конструкции. Заявка на изобретение РФ 201511480064. 20 апреля 2015.
  24. Dominici M., Le Blanc K., Mueller I. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Horwitz Cytotherapy 2006; 8(IV): 315-7.
  25. Cui F., Wang X., Liu X. et al. VEGF and BMP-6 enhance bone formation mediated by cloned mouse osteoprogenitor cells. Growth Factors 2010; 28(V): 306-17.
  26. Yin M., Pacifici M. Vascular regression is required for mesenchymal condensation and chondrogenesis in the developing limb. Dev. Dyn. 2001; 222(III): 522-33.
  27. Kubo S., Cooper G.M., Matsumoto T. et al. Blocking vascular endothelial growth factor with soluble Flt-1 improves the chondrogenic potential of mouse skeletal muscle-derived stem cells. Arthritis Rheum. 2009; 60(I): 155-65.
  28. Langenfeld E.M., Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol. Cancer Res. 2004; 2(III): 141-9.
  29. Закирова Е.Ю. Васин Н.Н., Катина М.Н. и др. Клинический опыт применения комбинированной генной терапии VEGF и ВМР2 в ветеринарии при восстановлении передней крестообразной связки у собаки крупной породы. Гены и Клетки 2014; 9tII): 93-5

Copyright (c) 2015 PJSC Human Stem Cells Institute


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 57156 от 11.03.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies